Recent observational studies have examined first-line EGFR TKI treatment patterns and outcomes for patients with EGFR-mutated advanced NSCLC (26–28); however, information remains limited regarding the outcomes of platinum-based regimens administered after disease progression on EGFR TKI therapy in real-world settings (29). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.